Table 3.
Summary of base case results
| Base case results | CSII arm | MDI arm | Difference |
|---|---|---|---|
| Discounted life expectancy (years) | 14.41 | 14.07 | 0.34 |
| Quality-adjusted life expectancy (QALYs) | 8.15 | 7.83 | 0.32 |
| Total cost, direct and indirect (EUR) | 133,259 | 118,053 | 15,206 |
| Total cost, direct costs only (EUR) | 104,145 | 86,865 | 17,280 |
| Treatment | 52,518 | 26,425 | 26,093 |
| Management | 10,124 | 9935 | 189 |
| Cardiovascular disease | 8633 | 8743 | − 110 |
| Renal disease | 12,053 | 17,829 | − 5776 |
| Ulcer/amputation/neuropathy | 2705 | 2832 | − 127 |
| Ophthalmic complications | 18,097 | 20,478 | − 2381 |
| Hypoglycemia | 0 | 607 | − 607 |
| Depression | 15 | 15 | 0 |
| ICER (EUR per QALY gained) | 47,834 | ||
CSII continuous subcutaneous insulin infusion, ICER incremental cost-effectiveness ratio, MDI multiple daily injections, QALY quality-adjusted life-year